SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas

Background: Relacorilant (RELA, Corcept Therapeutics) is a highly selective glucocorticoid receptor antagonist (GRA) that modulates the effects of excess cortisol, while showing no significant antagonism at the progesterone, mineralocorticoid, androgen, or estrogen receptors. It is currently being i...

Descripción completa

Detalles Bibliográficos
Autores principales: Terzolo, Massimo, Iacuaniello, Davide, Pia, Anna, Adriano, Priola, Moraitis, Andreas, Pivonello, Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552951/
http://dx.doi.org/10.1210/js.2019-SUN-463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552951/
http://dx.doi.org/10.1210/js.2019-SUN-463

Ejemplares similares